<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We describe three patients with primary <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and immunological manifestations </plain></SENT>
<SENT sid="1" pm="."><plain>One had painful cutaneous plaques, <z:hpo ids='HP_0001369'>arthritis</z:hpo> and <z:hpo ids='HP_0009830'>peripheral neuropathy</z:hpo>, another showed cutaneous <z:hpo ids='HP_0002633'>vasculitis</z:hpo>, and a third had <z:e sem="disease" ids="C0085077" disease_type="Disease or Syndrome" abbrv="">Sweet's syndrome</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients responded dramatically to steroids </plain></SENT>
<SENT sid="3" pm="."><plain>Before treatment the patient with <z:e sem="disease" ids="C0085077" disease_type="Disease or Syndrome" abbrv="">Sweet's syndrome</z:e> had high serum levels of interleukin 6 (IL-6), which were reduced to zero after treatment with steroids </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndrome</z:hpo> should be considered when evaluating patients with immunological or rheumatic manifestations associated with one or more cytopenias </plain></SENT>
</text></document>